Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes

Diabetes, Obesity and Metabolism

Volumn 16, Issue 7, 2014, Pages 628-635

  Dziuba, J ^a   Alperin, P ^a   Racketa, J ^b   Iloeje, U ^c   Goswami, D ^a   Hardy, E ^b   Perlstein, I ^c   Grossman, H L ^a   Cohen, M ^a  

^a Archimedes Inc   (United States)

^b ASTRAZENECA   (United Kingdom)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

Antidiabetic drug; Diabetes mellitus; Renal glucose handling; SGLT2 inhibitor; Type 2 diabetes; Weight loss therapy

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CHOLESTEROL; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA; TRIACYLGLYCEROL; 2,4-THIAZOLIDINEDIONE; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSE BLOOD LEVEL; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2; SULFONYLUREA DERIVATIVE; URIC ACID;

ADD ON THERAPY; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DEATH; DIABETIC RETINOPATHY; DIET; DISEASE COURSE; DISEASE DURATION; DRUG EFFECT; END STAGE RENAL DISEASE; FEMALE; FOOT AMPUTATION; HEALTH CARE QUALITY; HEALTH CARE SURVEY; HEALTH CARE SYSTEM; HEART INFARCTION; HUMAN; INCIDENCE; INSULIN TREATMENT; MALE; MICROANGIOPATHY; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRACTICE GUIDELINE; TREATMENT DURATION; AMPUTATION; ANTAGONISTS AND INHIBITORS; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR DISEASES; COMPARATIVE STUDY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; KIDNEY FAILURE, CHRONIC; METABOLISM; MICROCIRCULATION; MYOCARDIAL INFARCTION; NUTRITION; PATHOPHYSIOLOGY; STROKE; TREATMENT OUTCOME;

AMPUTATION; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC RETINOPATHY; DISEASE PROGRESSION; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; KIDNEY FAILURE, CHRONIC; METFORMIN; MICROCIRCULATION; MIDDLE AGED; MYOCARDIAL INFARCTION; NUTRITION SURVEYS; SODIUM-GLUCOSE TRANSPORTER 2; STROKE; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TREATMENT OUTCOME; URIC ACID;

EID: 84903175006     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12261     Document Type: Article

References (35)

1. World Health Organization Media Center Diabetes Fact Sheet. Available from URL: http://www.who.int/mediacentre/factsheets/fs312/en/index.html. Accessed 14 November 2012.
2. Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomized study. Lancet 1999; 353: 617-622.
3. Tzoulaki I, Molokhia M, Curcin V et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009; 339: b4731.
4. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. A Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012.
5. Ford ES. Trends in the risk for coronary heart disease among adults with diagnosed diabetes in the US. Diabetes Care 2011; 34: 1337-1343.
6. Ford ES. Trends in the control of risk factors for cardiovascular disease among adults with diagnosed diabetes: findings from the National Health and Nutrition Examination Survey 1999-2008. J Diabetes 2011; 3: 337-347.
7. Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 2011; 13: 928-938.
8. Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, on hemoglobin A1c, body weight, and hypoglycemic risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012; 35: 1473-1478.
9. Nauck MA, Prato SD, Meier JJ et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011; 34: 2015-2022.
10. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomized, double-blind, placebo-controlled trial. Lancet 2010; 375: 2223-2233.
11. Cefalu WT, Leiter LA, Debruin TW, Gause-Nilsson I, Sugg JE, Parikh SJ. Dapagliflozin treatment for type 2 diabetes mellitus patients with comorbid cardiovascular disease and hypertension. In: 72nd ADA Scientific Session Poster Presentation 2012, 1056-P
12. Leiter LA, Cefalu WT, Debruin TW, Gause-Nilsson I, Sugg JE, Parikh SJ. Efficacy and safety of dapagliflozin for type 2 diabetes mellitus patients with a history of cardiovascular disease. In: 72nd ADA Scientific Session Poster Presentation 2012, 1114-P
13. Gertler MM, Garn SM, Levine SA. Serum uric acid in relation to age and physique in health and in coronary heart disease. Ann Intern Med 1951; 34: 1421.
14. Ulmer H, Kelleher CC, Fitz-Simon N, Diem G, Concin H. Secular trends in cardiovascular risk factors: an age-period-cohort analysis of 698, 954 health examinations in 181, 350 Austrian men and women. J Intern Med 2007; 261: 566-576.
15. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: The Framingham heart study. Ann Intern Med 1999; 131: 7-13.
16. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality. The NHANES I epidemiologic follow-up study, 1971-1992. JAMA 2000; 283: 2404-2410.
17. Johnson RJ, Tuttle KR. Much ado about nothing, or much to do about something? The continuing controversy over the role of uric acid in cardiovascular disease. Hypertension 2000; 35: E10.
18. Baker JF, Krishnan E, Chen L, Schumacher HR. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med 2005; 118: 816-826.
19. Sakata K, Hashimoto T, Ueshima H, Okayama A, for the NIPPON DATA 80 Research Group. Absence of an association between serum uric acid and mortality from cardiovascular disease: NIPPON DATA 80, 1980-1994. Eur J Epidemiol 2001; 17: 461-468.
20. Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G. Uric acid and risk of myocardial infarction, stroke, and congestive heart failure in 417734 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med 2009; 266: 558-570.
21. Strasak AM, Kelleher CC, Brant LJ et al. Serum uric acid is an independent predictor for all major forms of cardiovascular death in 28613 elderly women: a prospective 21-year follow-up study. Int J Cardiol 2008; 125: 232-239.
22. Moriarity JT, Folsom AR, Iribarren C, Nieto FJ, Rosamond WD. Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk in Communities (ARIC) study. Ann Epidemiol 2000; 10: 136-143.
23. Hoieggen A, Alderman MH, Kjeldsen SE, Julius S et al, for the LIFE Study Group. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65: 1041-1049.
24. Athyros VG, Elisaf M, Papageorgiou AA et al, for the GREACE Study Collaborative Group. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis 2004; 43: 589-599.
25. Luk AJ, Levin GP, Moore EE, Zhou XH, Kestenbaum BR, Choi HK. Allopurinol and mortality in hyperuricemic patients. Rheumatology 2009; 48: 804-806.
26. ZHU Wen-hua, FANG Li-zheng, CH Li-ying, CHEN Zhou-wen, DAI-Hong-Lei, CHEN Jian-hua Follow-up study of programmed intervention of hyperuricemia in the prevention and treatment of cardiovascular morbid change Natl Med J China 2010; 90: 662-666.
27. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008; 359: 1811-1821.
28. Eddy DM, Schlessinger L. Archimedes: a trial-validated model of diabetes. Diabetes Care 2003; 26: 3093-3101.
29. Eddy DM, Schlessinger L. Validation of the Archimedes diabetes model. Diabetes Care 2003; 26: 3102-31110.
30. Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med 2005; 143: 251-264.
31. Alperin P, Soto-Campos G, Peskin B et al. Understanding the effect of glycemic control on macrovascular outcomes in patients with diabetes using the Archimedes model. American Diabetes Association Scientific Sessions: Orlando, FL, 2010.
32. The Mount Hood 4 Modeling Group. Computer modeling of diabetes and its complications. Diabetes Care 2007; 30: 1638-1646.
33. Ray KK, Seshasai SR, Wijesuriya S et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus; a meta-analysis of randomized controlled trials. Lancet 2009; 373: 1765-1772.
34. Schemacher HR, Becker MA, Wormann RL et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008; 59: 1540-1548.
35. Rosenstock J, Aggarwal N, Polidori D et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012; 35: 1232-1238.